Clinical Trials Browser

Phase 1 × Biliary Tract Neoplasms × 90 days × Clear all

Adenocarcinoma Of Esophagus, Biliary Tract Neoplasms, Neoplasm Metastasis, Stomach Neoplasms

NCT07334119 2026-02-19

Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors

BreastGastrointestinalGenitourinaryGynecologicThoracic

Adenocarcinoma Of Esophagus, Carcinoma, Ovarian Epithelial, Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT07197554 2026-02-18

A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies

Phase 1 Recruiting

171 enrolled

GastrointestinalGynecologicSarcoma

Biliary Tract Neoplasms, Carcinoma, Hepatocellular, Neoplasms, Sarcoma, Ewing, Endometrial Neoplasms

NCT07107750 2026-02-04

Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer

Phase 1 Not yet recruiting

48 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT06084481 2026-01-20

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

Phase 1 Active not recruiting

302 enrolled

BreastGastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Biliary Tract Neoplasms, Carcinoma, Hepatocellular, Triple Negative Breast Neoplasms

Clinical Trials

Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors

A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies

Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400